RING Finger Protein 10 Regulates AP-1/Meox2 to Mediate Pirarubicin-Induced Cardiomyocyte Apoptosis
Oxidative Medicine and Cellular Longevity · 2023
DOI: 10.1155/2023/7872193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, 2023. Verfasst von Hongwei Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Transcription Factor AP-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 7th Wuhan Young and Middle-aged Backbone Talent of Medical Training Project, Health Commission of Hubei Province, Chongqing Science and Health Joint Project.
Abstract (Originalsprache)
Pirarubicin (THP) is one of the classic chemotherapy drugs for cancer treatment. It is often clinically limited because of its cardiotoxicity. The occurrence and development of THP-mediated chemotherapy-related cardiotoxicity (CRC) may be reversed by RING finger protein 10 (RNF10). This study was performed with the aim of evaluating the inhibitory effect of RNF10 on THP-mediated CRC and its molecular mechanism. In vivo, we found that the expression of RNF10 decreased in THP-induced CRC rats, accompanied by Meox2 inhibition and AP-1 activation, resulting in increased cardiomyocyte apoptosis. After small interfering RNA (siRNA) and lentivirus transfection (Lv) of RNF10 in vitro, the expression of RNF10, Meox2, and AP-1 proteins and the degree of cardiomyocyte apoptosis were detected. We found that overexpression of RNF10 in H9C2 cardiomyocytes significantly promoted Meox2 and inhibited AP-1, alleviated apoptosis, and showed further inhibitory activity on THP-induced cardiomyocyte toxicity. Silencing RNF10 showed the opposite result. Our study showed that RNF10 inhibited THP-induced CRC through the activity of Meox2 and AP-1 proteins. RNF10 may be the next drug target for the treatment of CRC and other related cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Cardiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
ORCID-Profile: Hongwei Shi, Peng Pu, Heng Tang
Förderung
- 7th Wuhan Young and Middle-aged Backbone Talent of Medical Training Project
- Health Commission of Hubei Province
- Chongqing Science and Health Joint Project
Zitieren
APA
Shi, H., Duan, L., Lan, Y., He, Q., Pu, P., & Tang, H. (2023). RING Finger Protein 10 Regulates AP-1/Meox2 to Mediate Pirarubicin-Induced Cardiomyocyte Apoptosis. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2023/7872193
Vancouver
Shi H, Duan L, Lan Y, He Q, Pu P, Tang H. RING Finger Protein 10 Regulates AP-1/Meox2 to Mediate Pirarubicin-Induced Cardiomyocyte Apoptosis. Oxidative Medicine and Cellular Longevity. 2023. doi:10.1155/2023/7872193
BibTeX
@article{Shi2023,
author = {Shi, Hongwei and Duan, Liang and Lan, Ying and He, Quan and Pu, Peng and Tang, Heng},
title = {RING Finger Protein 10 Regulates AP-1/Meox2 to Mediate Pirarubicin-Induced Cardiomyocyte Apoptosis},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
doi = {10.1155/2023/7872193}
}
EUVIMED